This is a preview of subscription content, log in via an institution to check access.
Notes
The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial and the economic analysis were funded by Amgen Inc.
Reference
Belozeroff V, et al. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value in Health 18: 1079-87, No. 8, Dec 2015. Available from: URL: http://doi.org/10.1016/j.jval.2015.08.007
Rights and permissions
About this article
Cite this article
Is cinacalcet cost effective in sHPT in the US?. PharmacoEcon Outcomes News 744, 20 (2016). https://doi.org/10.1007/s40274-016-2724-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2724-y